Clinical Trial Update: G-Pola-GemOx in Refractory/Relapsed Aggressive B-Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial of the G-Pola-GemOx regimen for refractory/relapsed aggressive B-cell lymphoma is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aggressive B-cell Lymphoma

Drugs mentioned

• Gemcitabine (Gemzar) (gemcitabine)
• Oxaliplatin (Eloxatin) (oxaliplatin)
• Polatuzumab Vedotin (Polivy) (polatuzumab vedotin)
• Rituximab (Rituxan) (rituximab)

Snippet

Sponsor: Navy General Hospital, Beijing | Conditions: Aggressive B-Cell Lymphoma | Phase 2 | Status: NOT_YET_RECRUITING